Ligand Pharmaceuticals Incorporated (LGND) News
Follow Ligand Pharmaceuticals Incorporated (LGND) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 38 public stories across 20 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Ligand Reports Fiscal Q3 Profit Down 91.62%
Ligand reported fiscal third-quarter profit attributable to shareholders of 667.8万美元, down 91.62% year over year. Basic EPS was 0.33美元.
EQUITY | Nov 02, 2026, 04:06 AM UTC
M
Ligand Pharmaceuticals Reports Quarterly Results Through September 30
EQUITY | Oct 29, 2026, 07:13 PM UTC
M
Ligand Expects 2026 Revenue of $270M-$310M
Ligand Pharmaceuticals expects 2026 revenue of $270 million to $310 million, versus a FactSet estimate of $289.5 million.
EARNINGS | Oct 29, 2026, 11:28 AM UTC
M
Ligand Expects 2026 Adjusted EPS of $9.50-$9.75
Ligand Pharmaceuticals expects 2026 adjusted EPS of $9.50-$9.75, versus a FactSet estimate of $9.35.
EARNINGS | Oct 29, 2026, 11:27 AM UTC
M
Ligand Pharmaceuticals Q3 Royalty Revenue Jumps 51%
EQUITY | Oct 29, 2026, 11:23 AM UTC
M
Ligand Pharmaceuticals Swings to Q3 Net Loss of $28.49 Million
Ligand Pharmaceuticals reported a net loss of $28.49 million in Q3, compared with a profit a year earlier.
EQUITY | Oct 29, 2026, 11:22 AM UTC
M
Ligand Pharmaceuticals Posts Q3 Adjusted EPS of $2.67
Q3 adjusted EPS was $2.67 per share, versus the FactSet estimate of $2.33.
EARNINGS | Oct 29, 2026, 11:08 AM UTC
M
Ligand to report third-quarter 2026 results on October 29
EQUITY | Oct 15, 2026, 11:00 AM UTC
H
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call
On Thursday, Ligand Pharmaceuticals (NASDAQ: LGND ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts a
LIVE | Oct 07, 2026, 08:00 AM UTC
L
Weekly Recap: Ligand (LGND) $47M AvenCell funding and EMEA Ryjunea royalties
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is boosting its biopharma reach—financing AvenCell with up to $47M tied to AVC-201/AVC-203 royalties while securing EMEA royalties for Ryjunea, investing in Primrose Bio,
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Ligand Pharmaceuticals Price Target Announced at $345.00/Share by Barclays
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 12:40 PM UTC
L
Ligand Pharmaceuticals Price Target Maintained With a $358.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 04:04 PM UTC
L
Ligand Pharmaceuticals Incorporated (LGND) Funds AvenCell Up To $47M For Royalties
Ligand entered a financing agreement with AvenCell for up to $47M, including up to $41M tied to a royalty on sales of AvenCell assets and up to $6M in Series C funding. Funding is in four tranches, with later tranches co
NEWS | Sep 24, 2026, 11:01 AM UTC
L
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated NASDAQ:LGND today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell the
NEWS | Sep 24, 2026, 11:01 AM UTC
L
LGND - Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
LGND - Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
NEWS | Sep 24, 2026, 11:00 AM UTC
L
Ligand Pharmaceuticals Is Maintained at Buy by Citigroup
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 03:23 PM UTC
L
LGND - Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
LGND - Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
NEWS | Sep 22, 2026, 01:08 PM UTC
L
LGND - Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
LGND - Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
NEWS | Sep 22, 2026, 01:05 PM UTC
L
LGND - Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
LGND - Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
NEWS | Sep 22, 2026, 11:01 AM UTC
L
LGND: XOMA acquisition doubled the portfolio and set the stage for accelerated, diversified growth
LGND: XOMA acquisition doubled the portfolio and set the stage for accelerated, diversified growth
MNA | Aug 26, 2026, 04:11 PM UTC
L
LGND: XOMA acquisition and robust pipeline set the stage for accelerated, diversified growth
LGND: XOMA acquisition and robust pipeline set the stage for accelerated, diversified growth
MNA | Aug 26, 2026, 03:31 PM UTC
L
LGND - Ligand to Participate in September Investor Conferences
LGND - Ligand to Participate in September Investor Conferences
EQUITY | Aug 26, 2026, 11:00 AM UTC
L
Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.00
Ligand Pharmaceuticals (NASDAQ: LGND ) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to $270.000 million-$31
EARNINGS | Aug 06, 2026, 11:05 AM UTC
L
LGND - Ligand Reports Second Quarter 2026 Financial Results
LGND - Ligand Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 11:00 AM UTC
H
LGND PT Raised to $326
LGND price target increased to $326
EQUITY | Aug 03, 2026, 12:24 PM UTC
L
LGND Initiated Buy W/$387.00 PT at Citi
LGND Initiated Buy W/$387.00 PT at Citi
EQUITY | Jul 21, 2026, 12:09 PM UTC
L
LGND Resume coverage with a Buy/H rating, $387 PT @ Citi
LGND Resume coverage with a Buy/H rating, $387 PT @ Citi
EQUITY | Jul 21, 2026, 10:41 AM UTC
L
LGND Maintain Outperform, raise PT to $340 (from $262) as zero-coupon convert strengthens balance sheet @ RBC
LGND Maintain Outperform, raise PT to $340 (from $262) as zero-coupon convert strengthens balance sheet @ RBC
EQUITY | Jul 15, 2026, 12:32 PM UTC
H
Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase
() -- Ligand Pharmaceuticals (LGND) has completed its acquisition of XOMA Royalty (XOMA) for an equity value of about $739 million, the company said Tuesday. XOMA Royalty shareholders received $39 in cash per share and o
EARNINGS | Jul 14, 2026, 02:00 PM UTC
L
LGND Ligand completes acquisition of Xoma Royalty, creating a portfolio of more than 200 biopharmaceutical Royalty assets
LGND Ligand completes acquisition of Xoma Royalty, creating a portfolio of more than 200 biopharmaceutical Royalty assets
MNA | Jul 14, 2026, 01:00 PM UTC
H
Ligand price target raised to $388 from $266 at BofA
BofA analyst Jason Zemansky raised the firm's price target on Ligand to $388 from $266 and keeps a Buy rating on the shares. Despite strong share performance, Ligand's growth opportunity remains underappreciated, with th
EARNINGS | Jul 09, 2026, 10:19 AM UTC
L
Ligand Pharmaceuticals Insider Sold Shares Worth $1,566,377, According to a Recent SEC Filing
() -- Andrew Reardon, Chief Legal Officer & Secretary, on June 30, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,566,377. Following the Form 4 filing with the SEC, Reardon has control over a total of 41
REGULATION | Jul 06, 2026, 09:21 PM UTC
L
LGND Closes Notes Offering
Ligand announces closing of convertible senior notes offering
EQUITY | Jun 25, 2026, 08:01 PM UTC
L
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock
EQUITY | Jun 23, 2026, 09:24 AM UTC
M
LGND Prices $625M Notes
Ligand announces pricing of upsized $625 million convertible senior notes offering
EQUITY | Jun 23, 2026, 09:22 AM UTC
M
LGND Prices $625M Notes
Ligand Pharmaceuticals prices upsized $625M 0.0% convertible senior notes offering due 2031 and plans to repurchase shares
EARNINGS | Jun 23, 2026, 08:21 AM UTC
M
LGND Offers $550M Notes
Ligand plans to offer $550M in convertible notes for share buybacks and corporate needs
EQUITY | Jun 22, 2026, 11:15 AM UTC
M
LGND Offers $550M Notes
Ligand announces proposed offering of $550 million of convertible senior notes due 2031
EQUITY | Jun 22, 2026, 11:02 AM UTC